Neurogene, Inc. (NGNE)

NASDAQ

$32.05

$-0.40

(-1.25%)

Previous Close: ⁦$32.41⁩

Market Closed

Neurogene, Inc. (NGNE) Live Price Chart

Last updated: ⁦2026-09-20 17:42:40⁩. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.

Summary

Neurogene, Inc. (NGNE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $32.05, with a market capitalization of $642.17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15.93 to $43.66. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$642.17M
Open	$32.49
Day's High	$74.49
Day's Low	$6.88
Previous Close	$32.41
Volume	224.04K
Average Volume	255.74K
P/E Ratio	--
52-Week High	$43.66
52-Week Low	$15.93
Dividend Yield	--
Earnings Date	--

Neurogene, Inc. (NGNE) Latest Closing Stock Price

Neurogene, Inc. (NGNE) last closed at $32.41 as of 2026-09-18 23:31:00, unchanged from the previous close of $32.41.

During the latest regular trading session, NGNE traded between $6.88 and $74.49, with a volume of 224.04K shares. The closing price was near the middle and near the middle of its 52-week range.

Neurogene, Inc. (NGNE) 7-Day Stock Price Change

Over the past seven days, Neurogene, Inc. (NGNE) moved from $36.12 to $32.05, representing a decline of 11.26% ($4.07).

The stock traded between $31.73 and $38.25 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.

The average daily volume was 356.20 thousand shares, up versus the previous seven-day period, indicating higher trading activity.

NGNE 52-Week Price Position

Position in Range: 58.1%

52W Low$15.93

52W High$43.66

NGNE is currently trading at $32.05, placing it 58.1% of the way from its 52-week low of $15.93 to its 52-week high of $43.66. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Neurogene, Inc. (NGNE)?

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Neurogene, Inc. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	131
Exchange	NASDAQ
Company Website	https://www.neurogene.com

How to Buy Neurogene, Inc. (NGNE) Stock on MEXC

Eligible investors can buy real shares of Neurogene, Inc. (NGNE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for NGNE and Place Your Order

Open the RealStocks trading page and search for NGNE. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Neurogene, Inc. (NGNE) stock price today?

Neurogene, Inc. (NGNE) is currently trading at $ 32.05, down 1.10% ($0.36) from the previous close of $ 32.41. Intraday prices update in real time during regular trading hours.

2.Is NGNE stock going up or down today?

As of 2026-09-18 23:31:00, NGNE is trading at $ 32.05, down 1.10% ($0.36) from its previous close of $ 32.41. The stock has traded between $ 6.88 and $ 74.49 during today’s regular session. Past price movements do not guarantee future results.

3.What is NGNE pre-market price?

As of 2026-09-18 23:31:00, NGNE is trading at $ 32.43 in pre-market trading, up 0.06% ($0.02) from the previous close of $ 32.41. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is NGNE after-hours price?

As of 2026-09-18 23:31:00, NGNE is trading at $ 31.75 in after-hours trading, down 2.04% ($0.66) from the regular-session close of $ 32.41. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is NGNE stock trading now?

NGNE trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does NGNE sit relative to its 52-week high and low?

Over the past 52 weeks, NGNE has traded between a low of $ 15.93 and a high of $ 43.66. At $ 32.05, the stock is positioned 58.1% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Neurogene, Inc. in?

Neurogene, Inc. (NGNE) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Neurogene, Inc.'s market capitalization and where is it listed?

Neurogene, Inc. is listed on the NASDAQ exchange with a market capitalization of $ 642.17M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is NGNE valued in terms of P/E ratio and EPS?

NGNE trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -5.55. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Neurogene, Inc. pay a dividend?

Neurogene, Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.